An experimental drug improves patients’ blood sugar control without increasing the risk of low blood sugar hypoglycemia in patients with type 2 diabetes, according to the results of a phase 2 clinical trial.Type 2 diabetes is the more prevalent form of the disease, accounting for about 90 percent of cases. Often tied to obesity, type 2 diabetes involves a gradual decline in how insulin responds to changes in blood sugar glucose
Reposted by GentleCare Aston Pa. 19014